July 25 Company Quick Takes: RegenxBio, Neurimmune in neurodegenerative gene therapy deal; plus Lilly, Epizyme, ElevateBio and more

RegenxBio partners with Neurimmune, expands gene therapy pipeline
RegenxBio Inc. (NASDAQ:RGNX) and Neurimmune AG (Zurich, Switzerland) partnered to develop and commercialize gene therapies that use the former's NAV vectors to deliver antibodies to treat neurodegenerative diseases, starting with tauopathies. Financial terms were not disclosed. RegenxBio separately unveiled a preclinical hereditary angioedema gene therapy that delivers a gene encoding an antibody that targets and binds to plasma kallikrein.

FDA approves Lilly's nasal glucagon treatment
FDA approved Baqsimi nasal powder from Eli Lilly and Co. (NYSE:LLY) as the first non-injectable glucagon therapy to treat severe hypoglycemia. ...